Catalog No.
Product Name
Application
Product Information
Citations
-
Carbonic anhydrase inhibitor
Punicalagin is an ellagitannin, a type of phenolic compounds. It is a highly active carbonic anhydrase inhibitor.- Elizabeth Read, .et al. , ANIM FEED SCI TECH, 2019, May, 251(187-197)
-
Carbonic anhydrase inhibitor
Diclofenamide (or dichlorphenamide) is a sulfonamide and a carbonic anhydrase inhibitor of the meta-Disulfamoylbenzene class. -
carbonic anhydrase inhibitor
Dorzolamide HCl is a carbonic anhydrase inhibitor. It is an anti-glaucoma agent and topically applied in the form of eye drops. Dorzolamide HCl is used to lower increased intraocular pressure in open-angle glaucoma and ocular hypertension. -
hCA II inhibitor
EMAC10101d is a potent and selective inhibitor of Carbonic Anhydrase Isoform toward hCA II with an inhibitory activity in the low nanomolar range. Ki of 8.1 nM -
Carbonic Anhydrase Inhibitor
Methazolamide is an orally active inhibitor of carbonic anhydrase, demonstrating a Ki of 14 nM for human carbonic anhydrase II. This compound effectively reduces intraocular pressure and exhibits neuroprotective properties, including the ability to inhibit neuronal apoptosis. Methazolamide is applicable in research concerning ophthalmic diseases, such as glaucoma, and cerebrovascular conditions, including subarachnoid hemorrhage. -
Carbonic Anhydrase Probe
(+)-Xylariamide A is a potent probe for carbonic anhydrases, specifically targeting the β-carbonic anhydrases found in mycobacterial and fungal pathogens. It demonstrates significant inhibitory activity, making it a valuable tool for studying the role of carbonic anhydrases in microbial physiology and pathogenicity. Research applications include investigating antifungal and antibacterial mechanisms, as well as exploring therapeutic strategies against resistant strains. -
Carbonic Anhydrase Inhibitor
Zonisamide is an orally active inhibitor of carbonic anhydrases, demonstrating Ki values of 35.2 nM for human carbonic anhydrase II and 20.6 nM for human carbonic anhydrase V. This compound exhibits neuroprotective properties by promoting anti-apoptotic mechanisms and enhancing manganese superoxide dismutase (MnSOD) expression. Additionally, Zonisamide has been shown to upregulate Hrd1 expression, which contributes to improved cardiac function in animal models of cardiac hypertrophy. Research applications include investigations into seizures, Parkinson's disease, and cardiac hypertrophy. -
Carbonic Anhydrase/Alkaline Phosphatase Inhibitor
ALP/Carbonic Anhydrase-IN-1 is a dual inhibitor of carbonic anhydrase (CA) and alkaline phosphatase (ALP), selectively targeting key isoforms. It demonstrates IC50 values of 0.44 µM for CA-II, 1.61 µM for CA-IX, 0.51 µM for CA-XII, and 0.107 µM for ALP, indicating potent inhibitory activity. This compound is useful in exploring the roles of carbonic anhydrase and alkaline phosphatase in various biological processes and disease models. -
Carbonic Anhydrase Inhibitor
5,6-Dihydro-2H-pyran-2-one is a prodrug that functions as a selective inhibitor of carbonic anhydrases. It exhibits inhibitory activity against the tumor-associated isoform hCA IX and the cytoplasmic form hCA I, with Ki values of 1.35 μM and 8.03 μM, respectively. This compound is valuable for investigating mechanisms of hypoxia-related cancer, providing insights into tumor biology and potential therapeutic targets. -
Carbonic Anhydrase Inhibitor
2-Aminobenzenesulfonamide is an inhibitor of carbonic anhydrase IX, an enzyme implicated in various physiological processes, including respiration and acid-base balance. This compound exhibits significant biological activity, making it a valuable tool in cancer research and the study of metabolic disorders. Its ability to modulate carbonic anhydrase activity positions it as a potential lead compound for therapeutic development in conditions where altered enzyme activity plays a crucial role. -
Carbonic Anhydrase Inhibitor
Lasamide is a potent inhibitor of human carbonic anhydrases, specifically targeting hCAXII and hCAIX with Ki values of 7.54 nM and 2.76 nM, respectively. This compound exhibits significant biological activity in regulating pH and bicarbonate levels, making it valuable in research areas related to cancer, glaucoma, and metabolic disorders. Its specificity for human carbonic anhydrase isoforms allows for precise investigation of the enzyme's role in physiological and pathological processes. -
Carbonic Anhydrase Inhibitor
4-Chloro-3-sulfamoylbenzoic acid is a potent inhibitor of human carbonic anhydrase, specifically targeting cytosolic isoforms hCA I and hCA II, as well as transmembrane isoforms hCA IV and hCA IX. Its inhibition of these enzymes is significant in the study of glaucoma-associated conditions and tumor hypoxia-induced responses. This compound is valuable for research applications focused on exploring the roles of carbonic anhydrases in various physiological and pathological processes. -
COX-2/Carbonic Anhydrase Inhibitor
Polmacoxib is a novel, orally active nonsteroidal anti-inflammatory drug (NSAID) that acts as a dual inhibitor of cyclooxygenase-2 (COX-2) and carbonic anhydrase, with an IC50 value of approximately 0.1 μg/ml for COX-2. It exhibits significant biological activity by inhibiting the growth of colorectal adenomas and tumors in mouse models, making it a promising tool for cancer research. Polmacoxib is valuable for studying the roles of COX-2 and carbonic anhydrase in cancer biology and inflammation. -
Carbonic Anhydrase Inhibitor
hCAI/II-IN-6 is a selective inhibitor of human carbonic anhydrase isoforms II and VII, exhibiting Ki values of 4.9 nM and 6.5 nM, respectively. This compound demonstrates pronounced anticonvulsant activity and provides protective effects against maximal electroshock (MES) seizures in vivo. hCAI/II-IN-6 serves as a valuable tool for research studies focusing on epilepsy and related neurophysiological conditions. -
Carbonic Anhydrase II Inhibitor
Carbonic Anhydrase Inhibitor 2 specifically targets carbonic anhydrase II, functioning as an effective inhibitor. This compound is primarily used in research applications related to the modulation of intraocular pressure and may offer insights into potential therapeutic strategies for glaucoma. Its ability to influence carbonic anhydrase activity highlights its significance in biochemical studies and pharmacological investigations. -
Carbonic Anhydrase Inhibitor
hCAIX-IN-18 is a potent inhibitor of carbonic anhydrase (CA), demonstrating inhibition constants (Kis) of 3.5 nM, 9.4 nM, 43.0 nM, and 8.2 nM for human carbonic anhydrases I, II, IX, and XII, respectively. This compound is particularly relevant for cancer research, where it may affect tumor growth and metabolism through the modulation of CA activity. Its specificity and efficacy make it a valuable tool for investigating the role of carbonic anhydrases in various pathological conditions. -
Carbonic Anhydrase II Inhibitor
Dorzolamide is a potent inhibitor of carbonic anhydrase II, exhibiting an IC50 of 0.18 nM for red blood cell CA-II and 600 nM for CA-I. This compound is known for its therapeutic applications in reducing intraocular pressure and has demonstrated potential anti-tumor activity. It is a valuable reagent for research in cancer biology and ocular studies. -
Carbonic Anhydrase Inhibitor
Carbonic anhydrase inhibitor 17 is a pyridazine-tethered sulfonamide that specifically targets carbonic anhydrase II with an impressive IC50 value of 0.63 nM. This compound demonstrates potent inhibitory activity, making it a valuable tool for studying the role of carbonic anhydrases in various physiological and pathological processes. Its application is significant in research areas such as enzyme regulation, metabolic disorders, and cancer biology. -
Carbonic Anhydrase Inhibitor
AHR-15010 is a potent carbonic anhydrase inhibitor with an IC50 value of 0.13 μM. This compound exhibits anti-arthritic activity, making it a valuable tool for research on arthritis and related inflammatory conditions. Its ability to inhibit carbonic anhydrase opens avenues for studying therapeutic strategies in managing arthritis. -
Carbonic Anhydrase Inhibitor
hCAIX-IN-11 is a selective inhibitor of carbonic anhydrase IX (hCA IX) and XII (hCA XII), demonstrating Ki values of 32.7 nM and 623.5 nM, respectively. hCA IX and hCA XII are transmembrane isoforms that serve as biomarkers for various tumors, making them critical targets for cancer research. In addition to its role in tumor biology, hCA XII is involved in regulating acid-base homeostasis in both normal and cancerous cells, supporting its relevance in studies of metabolic regulation and tumor microenvironments. -
Carbonic Anhydrase Inhibitor
L-693612 is a potent, orally active carbonic anhydrase inhibitor. It effectively modulates bicarbonate and pH levels, making it a valuable tool for research into metabolic and respiratory disorders. This compound supports investigations into the therapeutic potential of carbonic anhydrase inhibition in various biological contexts. -
Carbonic Anhydrase Inhibitor
hCAII-IN-9 is a potent inhibitor of carbonic anhydrases, specifically exhibiting IC50 values of 1.18 μM for hCA II, 0.17 μM for hCA IX, and 2.99 μM for hCA XII. This compound demonstrates significant potential for research applications related to the modulation of carbonic anhydrase activity in various physiological and pathological conditions. Notably, hCAII-IN-9 does not exhibit permeability across the blood-brain barrier, making it suitable for studies focused on peripheral rather than central effects. -
Carbonic Anhydrase II Inhibitor
Carbonic Anhydrase Inhibitor 3 is a potent inhibitor of Carbonic Anhydrase II. This compound effectively reduces intraocular pressure, making it a valuable tool in the study of glaucoma and related ocular conditions. Its role in modulating intraocular pressure offers insights into therapeutic strategies for managing glaucoma. -
Carbonic Anhydrase II Inhibitor
Brinzolamide hydrochloride is a selective inhibitor of carbonic anhydrase II with an IC50 of 3.2 nM. It effectively lowers intraocular pressure (IOP) by targeting ciliary carbonic anhydrase II, leading to a reduction in aqueous humor secretion. This compound is particularly valuable for research applications related to glaucoma and other ocular conditions. -
Carbonic anhydrase Inhibitor
Dichlorphenamide disodium is a specific inhibitor of carbonic anhydrase, which functions by reducing the secretion of aqueous humor in the eye. This compound is effective in lowering intraocular pressure and is primarily utilized in glaucoma research. Its role in studying carbonic anhydrase inhibition provides insights into therapeutic strategies for managing elevated intraocular pressure and related ocular conditions. -
Carbonic Anhydrase Inhibitors
L-650719 is a potent carbonic anhydrase inhibitor, exhibiting a Ki value of 10 nM for carbonic anhydrase II (CA II). This compound has demonstrated significant efficacy in reducing intraocular pressure in rabbit models, highlighting its potential for therapeutic application. L-650719 is suitable for research focused on glaucoma and related ocular conditions. -
Carbonic Anhydrase Inhibitor
Carbonic Anhydrase Inhibitor 11 is a selective inhibitor targeting carbonic anhydrases, particularly exhibiting Ki values of 40 nM for CA II, 39 nM for CA IX, and 200 nM for CA XII. This compound demonstrates potential biological activity in modulating pH regulation and ion transport. It is valuable for research applications related to cancer, glaucoma, and other conditions where carbonic anhydrase plays a critical role in pathology. -
Carbonic Anhydrase Inhibitor
Carbonic anhydrase inhibitor 10 is a highly selective inhibitor of human carbonic anhydrase IX (hCA IX), with a Ki value of 6.2 nM. This compound demonstrates significant anti-proliferative activity in the MCF-7 cancer cell line, exhibiting an IC50 of 11.9 μM. Carbonic anhydrase inhibitor 10 is suitable for applications in cancer research, particularly in studies investigating the role of hCA IX in tumorigenesis and malignancy. -
Carbonic Anhydrase Inhibitor
Carbonic Anhydrase Inhibitor 13 is a potent inhibitor of carbonic anhydrase (CA), characterized by its 3-methylthiazolo[3,2-a]benzimidazole moiety linked to a zinc-coordinating benzenesulfonamide via a ureido linkage. This compound demonstrates significant inhibition of carbonic anhydrase activity, making it a valuable tool for investigating the role of CA in various physiological processes. Its applications extend to studies in cancer, glaucoma, and metabolic disorders, where modulation of CA activity may provide therapeutic insights. -
Carbonic Anhydrases Inhibitor
Antibacterial agent 167 is a potent inhibitor of pathogenic bacterial carbonic anhydrases. It demonstrates significant antibacterial activity against Neisseria gonorrhoeae strains, effectively inhibiting growth at concentrations between 16 and 64 µg/mL. This compound serves as a valuable tool for research into antibacterial mechanisms and the development of new therapeutic strategies against resistant bacterial infections. -
Carbonic Anhydrase Inhibitor
L-693612 hydrochloride is a potent inhibitor of carbonic anhydrase, demonstrating both oral and topical bioactivity. Its primary mechanism involves the inhibition of carbonic anhydrase enzymes, which play a critical role in regulating acid-base balance and fluid secretion. This compound is widely used in research applications targeting therapeutic areas such as glaucoma and edema, facilitating studies on the modulation of intraocular pressure and fluid management. -
Carbonic Anhydrase Inhibitor
HCAIX-IN-2 is a selective inhibitor of carbonic anhydrase, specifically targeting isoforms hCA IX and hCA XII with Ki values of 24.6 nM and 45.3 nM, respectively. This compound exhibits significant biological activity in modulating carbonic anhydrase activity, making it a valuable tool in cancer research and therapeutic development. Its inhibitory effects may provide insights into the role of carbonic anhydrases in tumor progression and offer potential avenues for treatment strategies. -
Carbonic Anhydrase Inhibitor
O-Desmethyl Brinzolamide hydrochloride is a potent carbonic anhydrase inhibitor, demonstrating a Kd of 0.136 nM for carbonic anhydrase II and an IC50 of 165 nM for carbonic anhydrase IV. This active metabolite of Brinzolamide is essential for research focused on the regulation of bicarbonate ions and pH homeostasis in various biological systems. It holds potential applications in studying conditions driven by abnormal carbonic anhydrase activity, including glaucoma and other metabolic disorders. -
Carbonic Anhydrase Inhibitor
Disulfamide is a potent carbonic anhydrase inhibitor with an IC50 value of 0.07 μM. By inhibiting carbonic anhydrase, Disulfamide disrupts the reabsorption of sodium and bicarbonate in the proximal tubule, leading to increased diuresis. This compound is valuable for research applications focusing on renal physiology and electrolyte balance. -
Carbonic Anhydrase Inhibitor
Clofenamide is a potent inhibitor of carbonic anhydrase (CA), an enzyme involved in maintaining acid-base balance and fluid homeostasis. This compound displays significant diuretic activity, making it valuable in research related to renal function and fluid regulation. Clofenamide is utilized in studies investigating the role of carbonic anhydrase in various physiological and pathological conditions. -
Carbonic Anhydrase Inhibitor
(Rac)-Sezolamide hydrochloride is a potent inhibitor of carbonic anhydrase, with a Ki value of 12.0 nM. This compound effectively lowers intraocular pressure (IOP), making it valuable for research into glaucoma and related ocular conditions. Its mechanism of action provides a useful tool for investigating the physiological and pharmacological pathways involved in eye health and disease. -
Human Carbonic Anhydrase Inhibitors
hCAI/II/XII-IN-1 is a potent inhibitor of human carbonic anhydrases I, II, and XII, exhibiting Ki values of 78.5 nM, 9.1 nM, 605 nM, 7.7 nM, and 3.7 nM for each isoform respectively. This compound demonstrates significant biological activity that can be leveraged in research applications targeting metabolic regulation, pH balance, and various diseases such as glaucoma and cancer. Its specificity and efficacy make it a valuable tool for investigating the role of carbonic anhydrases in physiological and pathological processes. -
Carbonic Anhydrase Inhibitor
Carbonic Anhydrase Inhibitor 12 is a selective inhibitor of carbonic anhydrase II (CA II), exhibiting a Ki value of 1.72 nM, and also demonstrating inhibitory activity against carbonic anhydrase I (CA I) with a Ki of 271 nM. This compound displays significant anticancer activity across various cancer cell lines, making it a valuable tool for cancer research and therapeutic development. Its ability to selectively target carbonic anhydrases influences pH regulation and may contribute to tumor growth modulation. -
Carbonic Anhydrase Inhibitor
Carbonic Anhydrase Inhibitor 9 is a selective inhibitor of carbonic anhydrases II and IX, exhibiting Ki values of 56.4 nM and 56.9 nM, respectively. This compound has demonstrated significant antiproliferative activity, making it a valuable tool for studying the role of carbonic anhydrases in cancer research and cellular metabolism. It serves as a potential therapeutic agent in conditions where modulation of carbonic anhydrase activity is desired. -
Carbonic Anhydrase Inhibitor
Carbonic Anhydrase Inhibitor 7 is a highly effective inhibitor of human carbonic anhydrase enzymes, with inhibition constants (Kis) of 6.5 nM for hCA IX, 7.1 nM for hCA II, 72.1 nM for hCA XII, and 255.8 nM for hCA I. This compound exhibits potent biological activity, making it a valuable tool for investigating the role of carbonic anhydrases in various physiological and pathological processes. It is particularly useful in cancer research and related fields where hCA IX is implicated. -
Carbonic Anhydrase Inhibitor
Sezolamide hydrochloride is a potent inhibitor of the enzyme carbonic anhydrase, primarily utilized in the context of ocular research. This compound effectively reduces intraocular pressure, making it valuable for studies related to glaucoma and other conditions affecting eye health. Sezolamide hydrochloride is instrumental in investigating the physiological mechanisms and therapeutic strategies for managing elevated ocular pressure. -
Carbonic Anhydrase 2 Inhibitor
GV2-20 is a potent inhibitor of Carbonic Anhydrase 2, demonstrating significant antiproliferative effects in chronic myeloid leukemia (CML) cells. This compound is valuable for research applications aimed at understanding the role of carbonic anhydrases in cancer biology and exploring potential therapeutic strategies for CML. Its selective inhibition may provide insights into cellular metabolism and proliferation mechanisms associated with cancer progression. -
Carbonic Anhydrase Inhibitor
Carbonic Anhydrase Inhibitor 4 is a selective inhibitor targeting human carbonic anhydrases (hCA I-XIV). With Ki values ranging from 640 to 1166 nM, it effectively modulates carbonic anhydrase activity. This compound is suitable for research applications involving enzyme inhibition studies and the investigation of physiological processes regulated by carbonic anhydrases. -
Carbonic Anhydrase Inhibitor
hCAIX-IN-10 is a selective inhibitor of carbonic anhydrases IX and XII, exhibiting Ki values of 61.5 nM and 586.8 nM for hCA IX and hCA XII, respectively. As transmembrane isoforms, hCA IX and hCA XII are recognized as key biomarkers for various tumors. The inhibition of these enzymes is pivotal in research focused on tumor progression, acid-base balance, and potential therapeutic strategies targeting cancer metabolism. -
Carbonic Anhydrase Inhibitor
Carbonic anhydrase inhibitor 6 is a potent inhibitor of human carbonic anhydrases (hCAs), exhibiting Ki values of 9.7 nM for hCA IX, 35.2 nM for hCA II, 88.5 nM for hCA XII, and 91.8 nM for hCA I. This compound is valuable for research applications targeting hCA-related pathways in cancer, glaucoma, and other diseases where carbonic anhydrases play a crucial role in regulating pH and fluid balance. Its high specificity and potency make it an essential tool for biochemical investigations and drug development efforts focusing on hCA modulation. -
Carbonic Anhydrase Inhibitor
Aminozolamide is a potent carbonic anhydrase inhibitor that plays a critical role in regulating intraocular pressure. By inhibiting carbonic anhydrase activity, Aminozolamide demonstrates effective local ocular effects and shows favorable retention within the ciliary body in rabbit models, reducing rapid elimination from the eye. This compound is applicable in the study of ocular hypertension and provides valuable insights into therapeutic interventions for managing elevated intraocular pressure. -
α-Carbonic Anhydrase Inhibitor
CAI0019 is an orally active inhibitor of α-carbonic anhydrase, designed based on the Acetazolamide framework. It demonstrates narrow-spectrum antibiofilm activity, with a MIC50 of 0.094 μM and a MIC90 of 0.39 μM. In a septic peritonitis mouse model, CAI0019 selectively inhibits Enterococcus while sparing most intestinal commensal bacteria, making it a valuable tool for research into antimicrobial therapies and biofilm-associated infections. -
Carbonic Anhydrase Inhibitor
Sezolamide is a potent inhibitor of carbonic anhydrase, primarily utilized for its ability to reduce intraocular pressure. Its mechanism of action involves the inhibition of carbonic anhydrase enzymes, which play a critical role in the regulation of bicarbonate and fluid balance in ocular tissues. This compound is valuable in research studies focused on glaucoma and other conditions associated with elevated intraocular pressure. -
Carbonic Anhydrase Inhibitor
(E)-Dehydrodiconiferyl alcohol is a dual inhibitor of human carbonic anhydrases IX and XII. This compound demonstrates significant biological activity by inhibiting NF-κB nuclear translocation in the connective tissues of healing areas. Its unique mechanism supports research in cancer biology and therapeutic approaches for inflammatory conditions. -
β-Carbonic Anhydrase Inhibitor
FC14-584B is a dithiocarbamate that serves as a β-Carbonic Anhydrase inhibitor. It effectively inhibits the growth of trophozoites and is applicable in research pertaining to tuberculosis. This compound may provide insights into the therapeutic approaches for diseases associated with dysregulated carbonic anhydrase activity.
